A study published in BMC Medicine (here) estimates
that the number of cancer deaths due to smokeless tobacco (ST) use in the U.S.
and Canada is ZERO.
The researchers, mainly from the UK, had bad news for ST
users in Southeast Asia, where products have high levels of contaminants and
are mixed with other toxic ingredients like betel. Deaths in that region contributed the lion’s
share of the worldwide toll of 267,000 annual deaths from cancer and heart
disease among ST users.
The researchers developed risk estimates based on
epidemiologic studies from each region.
As I have discussed many times, the risk of cancer among Swedish and
U.S. ST users is so small that it is not statistically significant. Attributing no U.S. cancer deaths to
smokeless tobacco use, the UK researchers confirmed this.
They also estimated deaths from ischemic heart disease among
ST users. I have noted that several
studies document the risk of heart attack among smokeless users in the U.S. and
Sweden as “next to nil” (here,
here,
here
and here). Ignoring these published risk estimates, the UK
researchers declared that “no good country-specific risk estimates were
available.” They assigned a risk value
of 1.6 based on an international heart attack study that included ST use data
from countries like Bangladesh, India, Pakistan, Sri Lanka, Nigeria and
Cameroon, but not the U.S. or Canada. Due
to this, the UK claim of 11,000 heart attack deaths in the U.S. and Canada from
ST use is a gross overestimate.
The U.S. and Canadian public should ignore scaremongering about ST deaths, as the real threat lies with adulterated products from
Southeast Asia. For Western ST users,
there is much to celebrate in this report.
3 comments:
Great news for smokeless tobacco users in northamerica glad some reaserch is being done
The BMC Medicine study is a bit confusing. Where should I see that Canada and the USA is zero cancer deaths?
Look in Table 4 at the row labeled "Americas A," which is the WHO region that includes the U.S., Canada and Cuba. There are zero deaths for mouth, pharyngeal and esophageal cancers.
Post a Comment